-
A Breakthrough for Chronic Skin Sensitivity: FDA Approves Rhapsido (remibrutinib)
A New Chapter for Symptomatic Dermographism For those living with symptomatic dermographism, even the slightest touch, scratch, or pressure can lead to uncomfortable, raised, red welts. For years, patients have struggled with the unpredictable nature of this skin condition. Recently, the landscape for treatment has shifted significantly with the FDA approval of Rhapsido (remibrutinib), developed…